(MENAFN- ProactiveInvestors) () was trading about 3% higher this morning as the US pharmaceutical group reported higher than expected earnings in the second quarter.
Gilead earned US$4.49 billion ($3.15 per share) against US$3.66 billion ($2.36 per share) a year ago on 26% higher revenues of US$8.24 billion. Analysts had expected US$2.71 a share on revenues of US$7.6 billion.
For 2015 the group is now targeting sales of between 29 and 30 billion dollars against a previous range of $ 28-29 billion.
One of the biggest drivers of the higher revenues was Gilead’s drug to treat hepatitis C Harvoni and Sovaldi which combined generated US$4.9 billion dollars in the second quarter higher than Wall Street expectations of about US$3.47 billion for Harvoni and US$928 million for Sovaldi according to StreetAccount.
Gilead now enjoys an over 90 percent market share for all hepatitis C patients according to Gilead's executive vice president of commercial operations Paul Carter:
"We see encouraging trends and remain highly confident" said Carter during an earnings call about the US and European market potential for its hepatitis C treatments.
Gilead is also known for its HIV treatment Truvada which also saw a notable 5% increase in sales compared to Q2 of 2014 reaching US$849 million higher also than analysts’ estimates of US$795.8 million.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.